A carregar...
Pazopanib and anti-VEGF therapy
Pazopanib (Votrient™, GlaxoSmithKline), a multi-kinase inhibitor with activity against VEGFR and other receptors, was recently approved by the FDA for the treatment of advanced renal cell carcinoma (RCC). Here, we review the history of its development, together with an overview of VEGF and its recep...
Na minha lista:
| Autor principal: | |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2010
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3818876/ https://ncbi.nlm.nih.gov/pubmed/24198612 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|